SLC22A3 that encodes organic cation transporter-3 is associated with prognosis and immunogenicity of human lung squamous cell carcinoma

Thuy-An Nguyen; Minh-Khang Le; Phuc-Tan Nguyen; Nguyen Quoc Vuong Tran; Tetsuo Kondo; Atsuhito Nakao

doi:10.21037/tlcr-23-334

SLC22A3 that encodes organic cation transporter-3 is associated with prognosis and immunogenicity of human lung squamous cell carcinoma

Transl Lung Cancer Res. 2023 Oct 31;12(10):1972-1986. doi: 10.21037/tlcr-23-334. Epub 2023 Oct 27.

Authors

Thuy-An Nguyen¹, Minh-Khang Le², Phuc-Tan Nguyen¹, Nguyen Quoc Vuong Tran¹, Tetsuo Kondo², Atsuhito Nakao^{1

3

4}

Affiliations

¹ Department of Immunology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
² Department of Human Pathology, University of Yamanashi, Yamanashi, Japan.
³ Yamanashi GLIA Center, University of Yamanashi, Yamanashi, Japan.
⁴ Atopy Research Center, Juntendo University School of Medicine, Tokyo, Japan.

Abstract

Background: SLC22A3, the gene which encodes organic cation transporter (OCT)-3, has been linked to the prognosis of several types of cancer. However, its role in lung squamous cell carcinoma (LSCC) has not been addressed elsewhere.

Methods: We analyzed gene expression, DNA methylation, and clinicopathological data from The Cancer Genome Atlas - Lung Squamous Cell Carcinoma (TCGA-LUSC) (n=501), a publicly available database exclusively consisting of LSCC patients. Using a 5 FPKM (fragments per kilobase of exon per million mapped fragments) cut-off, we divided LSCC patients into two groups: patients with tumors possessing high and low SLC22A3 expression (SLC22A3-high and SLC22A3-low, respectively). Prognostic significance was determined through Cox analyses and Kaplan-Meier curves for overall survival (OS) and disease-free survival (DFS). Differential methylation position (DMP), differentially gene expression, and pathway analyses were performed. Validation was carried out in GSE74777 (n=107), GSE37745 (n=66), GSE162520 (n=45) and GSE161537 (n=17).

Results: SLC22A3-high LSCC patients had lower OS and DFS rates than SLC22A3-low LSCC patients. The different expression levels of SLC22A3 in LSCC were correlated with the methylation status of the SLC22A3 gene. Pathway analysis indicated that SLC22A3 expression levels were positively correlated with immune-related pathways such as inflammatory response and abundance of infiltrating immune cells in the tumor microenvironment (TME). Notably, in the SLC22A3-high group, many genes encoding immunological checkpoint inhibitory molecules were upregulated. In addition, SLC22A3 expression positively correlated with the Hot Oral Tumor (HOT) score, indicating high tumor immunogenicity.

Conclusions: These findings suggest that high expression of SLC22A3 is associated with poor prognosis and high immunogenicity in LSCC tumors.

Keywords: Lung squamous cell carcinoma (LSCC); SLC22A3; biomarker; inflammation; tumor microenvironment (TME).